



Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins



Sara M. O'Rourke^a, Bin Yu^{a,b}, Javier F. Morales^{a,c}, Chelsea M. Didinger^a, David L. Alexander^a, Christopher Vollmers^a, Phillip W. Berman^{a,*}

^a Department of Biomolecular Engineering, The University of California at Santa Cruz, Santa Cruz, CA, USA

^b Askgene Pharma, Inc., Camarillo, CA 93021, USA

^c Eureka Therapeutics, Emeryville, CA 94608, USA

ARTICLE INFO

Keywords:

HIV-1 vaccine
CHO cells
Antibodies
Immunoaffinity chromatography

ABSTRACT

We have developed a stable Chinese Hamster Ovary (CHO) cell line for the production of a recombinant monoclonal antibody (mAb) to a short protein sequence derived from the N-terminus of human herpes simplex virus type 1 glycoprotein D (HSV-1 gD). The antibody (designated r34.1) provides a useful tool for the immunoaffinity purification of HSV-1 gD tagged proteins, and provides a generic purification system by which various proteins and peptides can be purified.

Recombinant 34.1 was assembled using cDNA derived from a HSV-1 gD specific murine hybridoma engineered to encode a full-length IgG molecule. Antibody expression cassettes were transfected into CHO-S cells, and a stable cell-line expressing up to 500 mg/L of antibody, isolated. Affinity purified r34.1 exhibited nanomolar affinity for its cognate ligand, and is stable throughout multiple cycles of immunoaffinity purification involving ligand binding at neutral pH, followed by acid elution. The HSV-1 gD tag expression and purification strategy has been used to enhance the secretion and purification of several vaccine immunogens including HIV envelope protein rgp120s, but the protocol has potential for generic application.

1. Introduction

Immunoaffinity purification of proteins tagged with short immunogenic sequences such as polyhistidine, c-myc and FLAG (Munro and Pelham, 1984; Evan et al., 1985; Hochuli et al., 1987; Hopp et al., 1988) have long been used as a convenient method to rapidly purify novel recombinant proteins. Early studies demonstrated improved recombinant gp120 expression when the endogenous HIV envelope secretory peptide was replaced with a HSV-1 gD signal peptide, and the first 11 amino acids of the mature form of gp120 were replaced with a 27 amino acid tag-sequence from the N-terminus of HSV-1 gD (Lasky et al., 1986; Berman et al., 1988). When the HSV-1 secretory signal/tag epitope sequences are incorporated into a protein, the signal peptide is removed during protein biosynthesis, and the resulting fully-processed protein possesses the N-terminal HSV-1 gD tag KYALADASLKMADPN-PFRGKDLPLVDQ. Incorporation of the tag enabled the development of a generic immunoaffinity purification process by which difficult to express rgp120's from multiple genetic clades could be purified.

Recombinant gp120s from the IIIB, MN, GNE8 and A244 strains of HIV-1 used in numerous clinical trials were manufactured as HSV-1-gD flag fusion proteins to facilitate expression and purification (Berman et al., 1990; Schwartz et al., 1993; Berman et al., 1994; Belshe et al., 1994; Berman et al., 1996; Berman et al., 1997; Gorse et al., 1999; Berman, 1998; Berman et al., 1999; Pitisuttithum et al., 2004; Flynn et al., 2005; Pitisuttithum et al., 2006; Rerks-Ngarm et al., 2009; Pitisuttithum et al., 2014), but to date, antibodies used in the purification process (Berman, 2015) have not been made widely available. The N-terminal region of HSV-1 gD has biological significance as it contains a fourteen amino acid receptor binding ligand for the herpes virus entry mediator A, (Carfi et al., 2001; Connolly et al., 2003) and is highly immunogenic with multiple overlapping T-cell and B-cell epitopes (Dietzschold et al., 1984; Heber-Katz et al., 1985; Heber-Katz et al., 1988; Cairns et al., 2015). It is also a target for human HSV-1 and HSV-2 neutralizing antibodies (Cairns et al., 2015) and multiple murine monoclonal antibodies (Dietzschold et al., 1984; Cohen et al., 1984; Eisenberg et al., 1985). In clinical trials, vaccination with the AIDS VAX B/E antigens

Abbreviations: rgD-gp120, recombinant gD tagged HIV-1 Env protein gp120; CHO-S, suspension adapted Chinese Hamster Ovary cells; HSV, Human Herpes Simplex Virus; cGMP, current Good Manufacturing Practice

* Corresponding author.

E-mail address: pwb@soe.ucsc.edu (P.W. Berman).

<https://doi.org/10.1016/j.jim.2018.11.015>

Received 28 September 2018; Received in revised form 27 November 2018; Accepted 27 November 2018

Available online 28 November 2018

0022-1759/ © 2018 Elsevier B.V. All rights reserved.

induced antibodies to both HIV and the HSV-1 gD peptide (Tomaras et al., 2013; Gilbert et al., 2017; Wang et al., 2017). While deletion of the first 11 amino acids from the mature form of gp120 prevented rgp120 dimerization, and improved the ability of the AIDS VAX B/E vaccine to induce specific types of HIV antibodies compared with wild-type gp120, insertion of the HSV-1 gD sequences did not impair HIV antibody production (Alam et al., 2013).

Here we describe the production of a recombinant murine HSV-1 gD antibody from a stable CHO-S cell line that is generally applicable for affinity purification of gD tagged proteins. The parental CHO-S cell line is a stable aneuploid cell line established from the ovary of an adult Chinese hamster (Tjio and Puck, 1958), distinguished as a separate subclone from the common CHO K1 cell line. Its history and stability have been extensively described (D'Anna et al., 1996; Deaven and Petersen, 1973; D'Anna et al., 1997).

2. Methods

2.1. Cell lines and culture conditions

Murine P3x63Ag8.653 cells were obtained from the American Type Culture Collection (ATCC). CHO-S cells were purchased from Thermo Fisher, Life Technologies (Carlsbad, CA). Immortalized hybridomas were prepared by fusion of hyper-immune spleen cells from immunized animals and screened a previous study (Morales et al., 2014), to select a wild type gD binding peptide sequence (KYALADASLKMADPNPFRGK-DLPVLDQLE) designated 34.1. The peptide includes a three amino acid spacer sequence included in the fusion protein (underlined). Monoclonal antibodies were raised according to the guidelines of the Animal Welfare Act, and the protocol approved by the Animal Care and Use Committee at the University of California at Santa Cruz. Static cultures were maintained in cell culture dishes and grown in a Sanyo incubator (Sanyo, Moriguchi, Osaka, Japan) at 37 °C, 8% CO₂, 85% humidity. For protein production, hybridomas were batch-cultured semi-adherent in DMEM supplemented with 5% FBS (Thermo Fisher, Life Technologies, Carlsbad, CA). Tissue culture supernatant was harvested by centrifugation followed by 0.2 µm filtration (Thermo Fisher, Hampton NH) before affinity purification on a HiTrap protein G column (GE Healthcare, Chicago, Chicago IL). CHO-S cells were maintained in CD-CHO medium (Glutamax (Thermo Fisher, Life Technologies, Carlsbad, CA) supplemented with 8 mM Glutamax. Suspension-adapted cells were maintained in shake flasks (Corning, Corning NY) using a Kuhner ISF1-X shaker incubator (Kuhner, Birsfelden, Switzerland). For normal cell propagation, shake flask cultures were maintained at 37 °C, 8% CO₂, 85% humidity and a rotation speed of 125 rpm. All cell counts were performed using a TC20™ automated cell counter (BioRad, Hercules, CA) with viability determined by trypan blue (Thermo Fisher, Life Technologies, Carlsbad, CA) exclusion.

2.2. Sequencing and molecular cloning

Total RNA was extracted from 1×10^7 34.1 hybridoma cells with RNeasyPlus (Qiagen Hilden Germany) and cDNA synthesized by reverse-transcription of template-primed with oligo-dT (Thermo Fisher Scientific Waltham, MA) using M-MuLV reverse-transcriptase (New England Biolabs Ipswich, MA) according to the manufacturers protocol. The light chain hypervariable region amplicon was obtained by Rapid Amplification of cDNA polymerase chain reaction (5' RACE PCR) (Ruberti et al., 1994; Doenecke et al., 1997) of total RNA followed by direct Sanger sequencing of the PCR product at the UC Berkeley Sequencing Facility. Sequence alignment of framework regions demonstrated a light chain kappa sequence. In order to express a complete light chain, a custom synthetic gene was designed to code a murine kappa secretory signal, the hyper-variable 34.1 kappa sequence and the constant region of a murine Ig kappa antibody (Svasti and Milstein, 1972) flanked by EcoRI and NotI restriction sites for cloning into an

expression vector. The heavy chain hypervariable sequence could not be obtained using the RACE PCR protocol. Instead, a single pair of degenerate primers (Fields et al., 2013) was used to produce the hypervariable heavy chain amplicon which was ligated into a TA shuttle vector pMD20 (Clontech Mountain View, CA) using standard molecular techniques, for sequencing. The resulting hyper-variable region sequences were aligned against the NCBI IgG database (<http://www.ncbi.nlm.nih.gov/igblast/>) to determine germline gene usage.

A full-length heavy chain antibody was engineered to consist of a murine kappa secretory signal, the hyper-variable 34.1 region sequence and a murine IgG₁ heavy chain Fc sequence (Honjo et al., 1979). Restriction enzyme sites (EcoRI and XbaI) were included at the 5' and 3' ends of the gene respectively, and a KpnI site at the Fc junction. Synthetic genes were purchased from Thermo Fisher Life Technologies (Carlsbad CA) and ligated via the restriction sites EcoRI and XbaI into a pCDNA3.1 (Thermo Fisher Life Technologies Carlsbad CA) derived vector, to construct two independent CMV transcription unit vectors. Plasmid DNA was prepared using the endotoxin free Qiagen Giga Prep purification kit (Qiagen, Hilden, Germany) and linearized by digestion with PvuI (New England Biolabs, Ipswich, MA) prior to electroporation.

2.3. Selection of a CHO-S cell line with stable high-level expression of recombinant 34.1 mAb

Light and heavy chain expression cassettes vectors were transfected into CHO-S cells at a ratio of 2:1 by electroporation using a Maxcyte STX, (MaxCyte Inc., Gaithersburg, MD) according to the manufacturer's instructions. Instead of using limiting dilution to select single cell clones, cells were seeded in methylcellulose CHO-Growth A, containing L-glutamine (Molecular Devices, Sunnyvale, CA), 500 µg/mL of G418 (Thermo Fisher Life Technologies, Carlsbad, CA) and 10 µg/mL of clone detect anti-murine FITC IgG (H and L) conjugate (Molecular Devices, Sunnyvale, CA) in 6-well plates (Greiner Kremsmünster, Austria). The plates were incubated in static culture for 13 days. Clones were then imaged and selected using the ClonePix2 robot. Before each procedure to isolate clones, the robot was sanitized and calibrated according to the manufacturer's instructions to ensure that the selected colonies were accurately isolated, and free from contamination. The plates were then imaged under white light, and also under fluorescence excitation (490/525 nm). Both images were superimposed to reveal an immunoprecipitin "halo" around a proportion of colonies. The colonies were then sorted according to rank of exterior fluorescent intensity "halo" (Lee et al., 2006) and default instrument parameters designed to select well separated compact colonies and exclude non-viable, and irregular ones. Forty-six individual clones with high exterior fluorescent intensity were aspirated with micro-pins controlled by the ClonePix2 system, and dispersed automatically in a 96 well plate (Greiner Kremsmünster, Austria) containing 100 µL of growth media in CD-CHO media supplemented with 8 mM Glutamax and 500 µg/mL G418/well. The selected clones could then be transferred for downstream applications.

Cultures were assayed for HSV-1 gD specific antibody production, then expanded into shake flasks culturing as CHO-S cells with the exception of adding G418 at a maintenance dose of 250 µg/mL. To evaluate stability, cells were continuously passaged and cryopreserved at regular intervals to evaluate antibody production over time. On completion of twenty-four passages, the cells were thawed and assayed for protein production.

2.4. Protein production

A single clone (D8) was scaled up for a 1.5 L (in duplicate) protein production experiment in Thomson 5 L flasks (VWR Radnor, PA). Cells were cultured in CD-OPTI CHO medium (Thermo Fisher Life Technologies, Carlsbad, CA) essentially as for transient antibody

production (Steger et al., 2015) that is by growth to a density of 1×10^7 cells/mL under standard conditions, then dropping the temperature to 32 °C, supplementing with 1 mM sodium butyrate, and feeding daily with Maxcyte CHO A Feed (0.5% Yeastolate (BD Franklin Lakes NJ, 2.5% CHO-CD Efficient Feed A, 0.25 mM Glutamax, 2 g/L Glucose (Sigma-Aldrich St. Louis, MO). Supernatant was harvested by pelleting the cells at 250 g for 30 min followed by pre-filtration through Nalgene™ Glass Pre-filters (Thermo Scientific Waltham, MA) and 0.45 µm SFCA filtration Nalgene (Thermo Scientific Waltham, MA), then stored frozen at -20 °C before chromatography purification.

2.5. Antibody specificity determination

Antibody binding to HSV-1 gD peptides was measured by a fluorescent immunoassay (FIA). Fluotrac high binding 96 well plates (Griener Bio-One Kremsmünster, Austria) were coated with 4 µg/mL HSV-gD peptides overnight in PBS, then blocked with 1%BSA/PBS 0.05% tween for 2 h. Three-fold serial dilutions of antibody were added to each well followed by Alexa 488 labelled polyclonal anti-species antibody (Jackson ImmunoResearch, West Grove PA) at a 1/5000 dilution. Incubations were performed for 90 min at room temperature followed by a 4× wash in PBS 0.05% tween buffer unless otherwise noted. Absorbance was read using an EnVision Multilabel Plate Reader (PerkinElmer, Inc. Waltham, MA) using a FITC 353 emission filter and FITC 485 excitation filter, and plotted on Graph Pad Prism 6 for Mac., GraphPad Software, La Jolla, CA.

Western blot was performed on dithiothreitol (DTT) reduced or non-reduced tissue culture supernatant (1 µL), or purified protein (50 ng) following electrophoresed on a 4–12% NuPage PAGE SDS gel, in MES buffer (Thermo Scientific Waltham, MA). Protein was transferred to a PDVF membrane using the iBlot 2 Dry Blotting System. The membrane was blocked for 1 h in 5% MILK/PBS then probed for 1 h at room temperature with agitation, with goat anti-mouse H and L chain specific horseradish peroxidase conjugated antibody (Jackson ImmunoResearch, West Grove, PA) at a concentration of 1 µg/mL in 5% milk PBS, and washed three times for 10 min each wash using 100 mL of 0.05%Tween/PBS. The membrane was developed using WesternBright ECL kit (Advanta Menlo Park, CA) and visualized using an Innotech FluoChem2 system (Genetic Technologies Grover, MO).

2.6. Binding affinity of recombinant 34.1 for to rgD-gp120

Kinetic experiments were conducted on a Biacore X100+ instrument (GE Healthcare, Chicago IL.) capturing r34.1 with an anti-murine Fc antibody covalently attached to a CM5 sensor chip at 100–150 RUs. This was accomplished by flowing r34.1 (1 µg/mL) over the chip for 30–60 s at a flow rate of 10 µL/min. Then a dilution series of gD tagged recombinant gp120 (analyte) from 100 to 1 µM, was passed over the chip to generate binding affinity data. The biosensor surface was regenerated with a 30s pulse of 10 mM Glycine pH 1.7 between injections (GE Healthcare, Chicago, IL.) BR-1008-38). All sensorgram data were globally fit to a 1:1 biomolecular binding model that included a mass transport term and processed using Biacore Evaluation software X100+ version 2.0.1 (GE Healthcare Chicago, IL.) to determine k_a , k_d , and K_D . χ^2 values < 1 and $R_{max} \leq 100$ were established as quality cut offs for acceptable data.

2.7. Anti-HSV-1 gD tag affinity column preparation and stability and quality testing

Recombinant 34.1 was coupled to Aminolink beads (Thermo Fisher Scientific, Waltham MA) according to the manufacturers instructions. Five mL Omnifit (Sigma Aldrich St. Louis MO.) columns were prepared for small-scale protein purification. For stability testing, multiple cycles of binding and elution of rgD-gp120 from the MGAT1⁻ A244_N332 line (O'Rourke et al., 2018) were completed. Each cycle compared binding

of 1 mg of rgD-gp120 per mg of antibody coupled beads using an ACTA column chromatography system (GE Healthcare Chicago IL). The binding and elution conditions were as follows; protein was captured from supernatant in 0.5 M NaCl, 0.1 M TMAC, 50 mM Tris, pH = 7.4, after a ten column volume wash with binding buffer, bound protein was eluted with 0.1 M NaOAc, pH = 3.0 before neutralizing with 1 M Tris-HCL pH 8.00, and concentration buffer exchange with a 30,000kD cutoff Amicon filter (Millipore, Burlington MA). Protein purified using the r34.1 affinity column was tested for CD4-IgG binding by direct binding ELISA as previously described (Morales et al., 2014; Doran et al., 2014) replacing bN-mAbs with the entry inhibitor CD4-IgG Capon (Capon et al., 1989).

3. Results and discussion

Recombinant gp120s, including Env proteins from the IIIB and A244 strains of HIV-1 used in numerous clinical trials, were manufactured as HSV-1-gD flag fusion proteins to facilitate expression and purification. These proteins were purified by a generic process that involved initial immunoaffinity purification, followed by a size exclusion chromatography polishing step. The CRF01AE A244 rgD-gp120 and IIIB clinical trial proteins were produced using a cGMP compliant affinity chromatography resin containing anti-gD monoclonal (5B6) mapping to the N-terminus of HSV-gD (Berman, 2015). The 5B6 antibody has subsequently been used to purify numerous rgp120s (Yu et al., 2012; Doran et al., 2018), including clade C viruses (Smith et al., 2010) and domain-fragments of gp120 (Morales et al., 2014; Nakamura et al., 1993; Nakamura et al., 2012) that were tested as immunogens, and used in mAb mapping studies. Since this antibody is not widely available, we produced an antibody with similar antigenic specificity to 5B6, similarly compatible with a HSV-1 gD tag purification system. HSV-1 gD is highly immunogenic, and multiple anti-gD antibodies have been described. Indeed, a robust anti-HSV gD response was raised during the RV144 clinical trial, which resulted in isolation of anti-gD monoclonal antibodies (Wang et al., 2017) and a follow up-study to determine if the response might protect against HSV-2 infection, was carried out (Gilbert et al., 2017). We previously reported selection of a murine hybridoma raised against a gD-tagged rgp140 that bound the wild type N terminal HSV-1 gD peptide sequence for use in immunoassays (Morales et al., 2014), but despite multiple sub-cloning attempts, the line was unstable in culture. Sequencing hyper-variable region light and heavy chain cDNA from the hybridoma, we expressed a recombinant IgG₁ using a stable transgenic CHO-S cell line. The recombinant antibody was purified from culture supernatant by standard chromatography methods, then covalently coupled to sepharose beads. Many monoclonal antibodies are acid labile, but r34.1 coupled beads were demonstrated to have minimal loss of affinity for ligand through multiple rounds of acid incubation followed by regeneration, a key requirement for an immunoaffinity substrate for a tag expression and purification system. Recombinant tagged envelope proteins rgD-gp120s purified on an r34.1 affinity column retain functional conformation as determined by the ability to bind the CD4 receptor.

3.1. Antibody reconstruction

Detailed sequence analysis revealed that the heavy chain hyper variable specificity determination sequences were quite short (GenBank Accession numbers MH813474 and MH813474). The heavy chain CDR1 and CDR2 are both eight amino acids long, and the CDR3 is 7 amino acids long. The light chain hyper-variable CDR1 was eleven amino acids long, the CDR2 three amino acids, and the CDR3 nine amino acids long. The highest homology matches in the IGBLAST database (Ye et al., 2013) were obtained against murine germline kappa-chain genes IGKV1-117*01, IGKJ1*01, and IGKJ1*02, and murine heavy chain germline IGHV1-2*02, IGHV6-13*01, and IGHJ1*01 genes. Aligning the framework regions, it was possible to design

Table 1
Recombinant 34.1mAb light and heavy chain sequences.

> 34.1 light chain
<i>MGWSCILFLVATATGVHSGVVMQIOTPLSLPVLGDAQSISCRSGQSLVHNDGDYTLH- WYLKQPGQSPKLLIYRVSNRFSGVPDRFSGSGTDFTLRISRVEAEDLGIYFCS- QSTYVPLTFGAGTKLELRADAAPTIVSIFPPSEQLTSGGASVVCFLNFPKDI- VKWKIDGSRQNGVLSWTDQSDKSTYSMSSTLTLTKDEYERHNSYTC EATHKT- STSPVSKFNRNEC*</i>
> 34.1 heavy chain
<i>MGWSCILFLVATATGVHSIEVKLQSGAELVRPGASVKLSCTASGFNIKDDYI HWVKQRPEQGLEWIGWIDPENGDT EYASKFQ GKATITADTSSNTAYLQSLSLTS- EDTAVYYCSKPPWFAYWGQGLTIVTSAAKTTPPSVYPLAPGSAQTNSMVTLGC- LVKGYFPEPVTVTWNSSGLSSGVHTFPAVLQSDLYTLSSVTVPSRPRSETVTCNV- AHPASSTKVDKIVPRDCGCKPCICTVPEVSSVFIFFPKPKDVLITLTPKVTCTVVVDI- SKDDPEVQSFVWVDDVEVHTAQTPREEQFNSTFRSVELPIDWLNKGEFKCRVN- SAAFPAPIEKTSKTKGRPKAPQVYTIPTPKQMAKDKVSLT CMITDFPEDITVEW- QWNGQPAENYKNTQPI MNTNGSYFVYSKLVNQQSNWEAGNTFTCSVLH EHLHN- HHTKLSLHSPGK*</i>

Secretory peptide in italics, 34.1 hypervariable coding region in bold, non-
bolded script, constant region sequence.

synthetic DNA sequences to re-engineer the full-length light and heavy
chains from available data (Table 1).

Although the original 34.1 mAb was determined to be isotype IgG₁,
the antibody was reconstructed as an IgG₁ with three rather than two,
inter-heavy chain disulfide bonds. Genes were expressed on two sepa-
rate plasmids under the control of a CMV mammalian expression cas-
sette based on the pcDNA3.1 vector (Thermo Fisher Life technologies,
Carlsbad), modified by the addition of a chimeric intron between the
start of transcription and the start of translation.

3.2. Stable CHO-S r34.1 clone selection

Stable G418 resistant CHO-S lines were generated using a ClonePix2
(Molecular devices Sunnyvale, CA) robot, following electroporation of
CHO-S cells with linearized vector light and heavy chain, and selection
using G418. Colonies were visualized using white light. When illumi-
nated by 490 nm wavelength light, colonies actively secreting IgG have
a green precipitin “halo” visible at 525 nm (Fig. 1 A and B). The mean
exterior fluorescence intensity of the halos was ranked, and those with
the highest intensity (forty-two colonies) robotically picked. Selected
colonies were propagated and assayed by ELISA and western blot. Of
these, a single clone (D8) in Fig. 1C, was chosen based on a combination
of expression, secreted light: heavy chain ratio, and cell line growth,
and designated CHO-S r34.

The cell line CHO-S r34.1 (D8) was and assayed for protein pro-
duction (Fig. 2) by seeding duplicate 1500 mL cultures at 5×10^5 cells/
mL at 37 °C. After four days of growth, sodium butyrate was added
(1 mM), and the temperature dropped to 32 °C. The culture was fed

daily as previously described. A viable cell density of between 0.5 and
 1×10^7 cells /mL was maintained for 13 days (Fig. 2A) with a per-
centage viability of > 80% (Fig. 2B). The culture yielded 360–380 mg/L
of antibody after 13 days (Fig. 2C). Antibody was clearly the dominant
protein accumulating in conditioned media from day 7 of culture
(Fig. 2D), facilitating subsequent protein purification.

Protein productivity fell from in the region of 480 mg to 350 mg of
antibody per liter determined by quantitative immunoassay over the
course of 24 passages (Fig. 3A), comparable to that observed previously
(Svasti and Milstein, 1972) for CMV driven protein expression in CHO-S
cells with G418 maintenance pressure. The doubling time remained
constant at approximately 24 h (Fig. 3B), which is slightly slower than
the parental CHO-S line (approximately 20 h).

Antibody was purified using standard Protein G affinity chromato-
graphy, followed by size exclusion gel chromatography on an Superdex
200 (GE Healthcare, Chicago IL.) then concentrated with an 30,000 kDa
cutoff filter (Millipore, Burlington, MA.) and stored at -20 °C. A gel
filtration analysis of the protein G-purified material is shown in Fig. S1.

3.3. Anti-HSV-1 flag antibody gD binding specificity

Critical amino acids in the r34.1 mAb epitope were mapped using a
set of HSV-gD peptides (Table 2). Peptide mapping revealed a role for
the sequence “KDL” and possibly “LV” corresponding to amino acids
20–22 and 24–25 of the HSV-gD sequence (Fig. 4 and Table 2).

The r34.1 mAb binds wild type HSV-gD peptide, and N and C
terminal deletion mutants with an EC₅₀ of 0.39–0.42 µg/mL (in the nM
range) in direct binding immunoassay. In the absence of “KDL” and
“LV” amino acids, all HSV-gD binding is lost. Proline at position 23 is
not required.

To verify production of an antibody that binds the gD flag in the
context of a fusion protein, we measured the kinetics of r34.1 binding to
a rgD-gp120 using surface flow plasmon resonance. We determined the
K_D to be 16 nM with an on-rate of approximately 2.5×10^5 M⁻¹ s⁻¹
and an off-rate of 3.5×10^{-3} s⁻¹ (Fig. 5). Although the antibody has a
high affinity for its ligand, the antibody/ ligand complex is weak or
unstable as indicated by the fast off rate, an ideal characteristic for an
immunoaffinity substrate.

3.4. Anti-HSV-1 gD tag affinity column preparation and stability testing

The choice of coupling chemistry is critical in the preparation of an
affinity column, and typically determined empirically. We tested two
resins; coupling recombinant antibody to a cyanogen bromide-activated
resin resulted in an affinity column with low stability that leached
antibody after 11 cycles (Fig. S2) whereas r34.1 captured on aldehyde
cross-linked beads retained 80% binding capacity through 18 cycles of
protein capture followed by acid elution at pH 3.00 and re-equilibration
(Fig. 6A). An area under the curve analysis of the chromatograms is




Fig. 1. Selection of colonies expressing murine IgG antibodies using the ClonePix2 robot. A G418 selected colonies visible in 35 mm well illuminated with white light after 10 days in culture. B The same wells illuminated with 490 nm wavelength light. Colonies actively secreting IgG have a green “halo” visible at 525 nm. C well 3 from image B, with white and FITC images superimposed. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 2. CHO-S r34.1 (clone D8) growth. Cell culture is described in section 2.4. Temperature shift (to 32 °C) and the addition of 1 mM sodium butyrate, is indicated by an arrow. A Timecourse graph of viable cell densities (VCD) determined by trypan-blue exclusion. B Time course of cell viabilities determined by trypan-blue exclusion. C Time course of r34.1 production determined by quantitative immunoassay. D SDS PAGE of DTT reduced conditioned media stained with Coomassie blue (left) or western blotted detecting with rabbit anti-murine (H and L) antibody (right) as described in Section 2.5. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 3. Stability testing of CHO-S r34.1 (clone D8). A Protein productivity of cells isolated at three time points over the course of a 24 passage culture. B Viable cell density. Cells were continuously cultured re-seeding a density of 3×10^5 or 5×10^5 cells per mL at 4 and 3 day intervals counting prior to each split to record growth.

Table 2
HSV-1gD peptides used in recombinant antibody mapping.

Peptide	Domain	Sequence	r34.1 mAb EC50 μ g/mL
1. WT gD	Wild type	KYALADASLKMADPNRFRGKDLPLVDQ <u>LL</u> E	0.40
2. gD_ΔNterm	3 aa N-terminus deletion	LADASLKMADPNRFRGKDLPLVDQ <u>LL</u> E	0.42
3. gD_ΔC5aa	5 aa C -terminus deletion, ΔP	KYALADASLKMADPNRFRGKDLVL	0.39
4. gD_ΔC10aa	10aa C -terminus deletion	KYALADASLKMADPNRFRG	No Binding

Fusion protein linker underlined.

Peptides synthesized by GenScript, Inc. (Piscataway, NJ).

EC50 was calculated from a plot of log (agonist) vs response –variable slope (four parameters) on Graph Pad Prism 6 for Mac., GraphPad Software, La Jolla, CA.




Fig. 4. Epitope mapping using a series of HSV-1gD peptides. Antibody binding was assayed by direct binding of the recombinant antibody to HSV-1 gD peptide coated plates as described in Section 2.5 and Table 2.

given in Fig. 6B. Gel electrophoresis of starting material, unbound flow through, and purified protein is given in Fig. 6C with 5B6 purified protein for comparison. The aldehyde-activated cross-linked agarose bound r34.1 to a capacity of 4 mg of antibody to each mL of beads




Fig. 5. Sensogram of gD-rgp120 binding to immobilized recombinant 34.1 antibody. A concentration range of 1–100 μM was assayed (Section 2.6) and data evaluated using Biacore Evaluation software (GE Health Sciences).

following coupling performed according to the manufacturer's protocol, and had a maximum ligand-binding dynamic capacity of 5 mg/mL (Fig. 6).

3.5. HSV-1 gD-tag purification with r34.1

In summary, we recovered the hypervariable-region genes that code specificity to herpes simplex virus type 1 glycoprotein D from a mouse hybridoma. The genes were used them to engineer a stable CHO-S line that secretes high levels of this antibody. Subsequent studies have demonstrated that the cell line maintains an acceptable level of productivity for > 20 passages, and that the antibody is stable to repeated cycles of acid elution and regeneration required for immunoaffinity chromatography purification of HSV-1gD-tagged proteins.




Fig. 7. CD4-IgG binding to affinity-purified rgD-gp120.

Recombinant mAb 34.1 is a murine IgG1 that binds to gD-tagged fusion proteins with nanomolar affinity. Although we did not definitively map the r34.1 epitope, it appears to bind a short linear epitope (KDL) that overlaps with the human CH43 mAb epitope derived from an individual immunized with rgD-gp120 during the course of the RV44 HIV trial (Wang et al., 2017). We have recently used the generic r34.1 affinity/size exclusion process to purify rgD-gp120 protein antigens (Yu et al., 2012) Byrne et al., 2018, #5209; O'Rourke et al., 2018, #24921; Doran et al., 2018, #78045} and several rgp120 fragments currently under evaluation as new immunogens. Proteins purified using 5B6 and r34.1 affinity columns have identical binding to rCD4-IgG which is a surrogate measure of protein folding (Fig. 7).

Binding of CD4-IgG to rgD-gp120 purified on either 5B6 or r34.1 immunoaffinity columns, was measured by capture ELISA, immobilizing rgD-gp120 on r34.1 coated wells.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jim.2018.11.015>.




Fig. 6. Dynamic binding capacity of r34.1 aldehyde coupled agarose affinity column. A Chromatograms of 18 sequential immunoaffinity rgD-gp120 purification experiments superimposed, eluting ligand at pH 3.0, and regenerating the column between runs. C Area under the curve analysis of the data shown in A, to calculate percentage protein recovery through successive column runs. B SDS PAGE electrophoresis of rgD-gp120 purified on an r34.1 or 5B6 immunoaffinity column. Starting material (conditioned media, FT flow through (non bound) and B bound and eluted, or purified protein, are indicated.

Funding

This work was supported by NIAID grants AI 089378 and AI 112893 and NIDA grant DA26801 to PWB.

Acknowledgments

We would like to thank Global Solutions for Infectious Diseases for providing samples of 5B6 antibody coupled resin, Kathryn A. Mesa for laboratory management, and Dr. Lucy Yin for additional purification advice.

References

- Alam, S.M., Liao, H.X., Tomaras, G.D., Bonsignori, M., Tsao, C.Y., Hwang, K.K., et al., 2013. Antigenicity and immunogenicity of RV144 vaccine AIDSvax clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. *J. Virol.* 87, 1554–1568.
- Belshe, R.B., Graham, B.S., Keefer, M.C., Gorse, G.J., Wright, P., Dolin, R., et al., 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. *NIAID AIDS Vaccine Clin. Trials Network* 272, 475–480.
- Berman, P.W., 1998. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. *AIDS Res. Hum. Retrovir.* 14 (Suppl. 3), S277–S289.
- Berman, P.W., 2015. Strategies for Improving the AIDSvax Vaccines. (NIAID HIV Env Manufacturing Workshop).
- Berman, P.W., Nunes, W.M., Haffar, O.K., 1988. Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines. *J. Virol.* 62, 3135–3142.
- Berman, P.W., Gregory, T.J., Riddle, L., Nakamura, G.R., Champe, M.A., Porter, J.P., et al., 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. *Nature* 345, 622–625.
- Berman, P.W., Eastman, D.J., Wilkes, D.M., Nakamura, G.R., Gregory, T.J., Schwartz, D., et al., 1994. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. *AIDS* 8, 591–601.
- Berman, P.W., Murthy, K.K., Wrin, T., Vennari, J.C., Cobb, E.K., Eastman, D.J., et al., 1996. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. *J. Infect. Dis.* 173, 52–59.
- Berman, P.W., Gray, A.M., Wrin, T., Vennari, J.C., Eastman, D.J., Nakamura, G.R., et al., 1997. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. *J. Infect. Dis.* 176, 384–397.
- Berman, P.W., Huang, W., Riddle, L., Gray, A.M., Wrin, T., Vennari, J., et al., 1999. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. *Virology* 265, 1–9.
- Cairns, T.M., Huang, Z.Y., Gallagher, J.R., Lin, Y., Lou, H., Whitbeck, J.C., et al., 2015. Patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific. *J. Virol.* 89, 9213–9231.
- Capon, D.J., Chamow, S.M., Mordenti, J., Marsters, S.A., Gregory, T., Mitsuya, H., et al., 1989. Designing CD4 immunoadhesins for AIDS therapy. *Nature* 337, 525–531.
- Carfi, A., Willis, S.H., Whitbeck, J.C., Krummenacher, C., Cohen, G.H., Eisenberg, R.J., et al., 2001. Herpes simplex virus glycoprotein D bound to the human receptor HveA. *Mol. Cell* 8, 169–179.
- Cohen, G.H., Dietzschold, B., Ponce De Leon, M., Long, D., Golub, E., Varrichio, A., et al., 1984. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. *J. Virol.* 49, 102–108.
- Connolly, S.A., Landsburg, D.J., Carfi, A., Wiley, D.C., Cohen, G.H., Eisenberg, R.J., 2003. Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. *J. Virol.* 77, 8127–8140.
- D'Anna, J.A., Crissman, H.A., Valdez, J.G., Gurley L.R., Tobey, R.A., 1996. Synchronization of mammalian cells in S phase by sequential use of isoleucine-deprivation G1- or serum-withdrawal G0-arrest and aphidicolin block. *Methods Cell Sci.* 18 (2), 115–125.
- D'Anna, J.A., Valdez, J.G., Habbersett, R.C., Crissman, H.A., 1997. Association of G1/S-phase and late S-phase checkpoints with regulation of cyclin-dependent kinases in Chinese hamster ovary cells. *Radiat. Res.* 148, 260–271.
- Deaven, L.L., Petersen, D.F., 1973. The chromosomes of CHO, an aneuploid Chinese hamster cell line: G-band, C-band, and autoradiographic analyses. *Chromosoma* 41, 129–144.
- Dietzschold, B., Eisenberg, R.J., Ponce De Leon, M., Golub, E., Hudecz, F., Varrichio, A., et al., 1984. Fine structure analysis of type-specific and type-common antigenic sites of herpes simplex virus glycoprotein D. *J. Virol.* 52, 431–435.
- Doenecke, A., Winnacker, E.L., Hallek, M., 1997. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. *Leukemia* 11, 1787–1792.
- Doran, R.C., Morales, J.F., To B, Morin, T.J., Theolis Jr., R., O'Rourke, S.M., et al., 2014. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. *Mol. Immunol.* 62, 219–226.
- Doran, R.C., Tatsuno, G.P., O'Rourke, S.M., Yu, B., Alexander, D.L., Mesa, K.A., et al., 2018. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. *PLoS One* 13, e0196370.
- Eisenberg, R.J., Long, D., Ponce De Leon, M., Matthews, J.T., Spear, P.G., Gibson, M.G., et al., 1985. Localization of epitopes of herpes simplex virus type 1 glycoprotein D. *J. Virol.* 53, 634–644.
- Evan, G.I., Lewis, G.K., Ramsay, G., Bishop, J.M., 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol. Cell. Biol.* 5, 3610–3616.
- Fields, C., O'Connell, D., Xiao, S., Lee, G.U., Billiald, P., Muzard, J., 2013. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. *Nat. Protoc.* 8, 1125–1148.
- Flynn, N.M., Forthal, D.N., Harro, C.D., Judson, F.N., Mayer, K.H., Para, M.F., 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *J. Infect. Dis.* 191, 654–665.
- Gilbert, P.B., Excler, J.L., Tomaras, G.D., Carpp, L.N., Haynes, B.F., Liao, H.X., et al., 2017. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. *PLoS One* 12, e0176428.
- Gorse, G.J., Patel, G.B., Mandava, M., Berman, P.W., Belshe, R.B., 1999. MN and IIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. *National Institute of Allergy and Infectious Disease AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retrovir.* 15, 921–930.
- Heber-Katz, E., Hollosi, M., Dietzschold, B., Hudecz, F., Fasman, G.D., 1985. The T cell response to the glycoprotein D of the herpes simplex virus: the significance of antigen conformation. *J. Immunol.* 135, 1385–1390.
- Heber-Katz, E., Valentine, S., Dietzschold, B., Burns-Purzycki, C., 1988. Overlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHC restriction elicited, and functional evidence for antigen-Ia interaction. *J. Exp. Med.* 167, 275–287.
- Hochuli, E., Döbeli, H., Schacher, A., 1987. New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. *J. Chromatogr. A* 411, 177–184.
- Honjo, T., Obata, M., Yamawaki-Katoaka, Y., Kataoka, T., Kawakami, T., Takahashi, N., et al., 1979. Cloning and complete nucleotide sequence of mouse immunoglobulin gamma 1 chain gene. *Cell* 18, 559–568.
- Hopp, T.P., Prickett, K.S., Price, V.L., Libby, R.T., March, C.J., Cerretti, D.P., et al., 1988. A short polypeptide marker sequence useful for recombinant protein identification and purification. *Nat. Biotechnol.* 6, 1204.
- Lasky, L.A., Groopman, J.E., Fennie, C.W., Benz, P.M., Capon, D.J., Dowbenko, D.J., et al., 1986. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. *Science* 233, 209–212.
- Lee, C., Ly, C., Sauerwald, T., Kelly, T., Moore, G., 2006. High-throughput screening of cell lines expressing monoclonal antibodies. *Bioprocess Int.* 4, 32–35.
- Morales, J.F., Morin, T.J., Yu, B., Tatsuno, G.P., O'Rourke, S.M., Theolis Jr., R., et al., 2014. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1. *J. Biol. Chem.* 289, 20526–20542.
- Munro, S., Pelham, H.R., 1984. Use of peptide tagging to detect proteins expressed from cloned genes: deletion mapping functional domains of *Drosophila* hsp 70. *EMBO J.* 3, 3087–3093.
- Nakamura, G.R., Byrn, R., Wilkes, D.M., Fox, J.A., Hobbs, M.R., Hastings, R., et al., 1993. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. *J. Virol.* 67, 6179–6191.
- Nakamura, G.R., Fonseca, D.P., O'Rourke, S.M., Vollrath, A.L., Berman, P.W., 2012. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of alpha4beta7 binding. *PLoS One* 7, e39045.
- O'Rourke, S.M., Byrne, G., Tatsuno, G., Wright, M., Yu, B., Mesa, K.A., et al., 2018. Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production. *PLoS One* 13, e0197656.
- Pitisuttithum, P., Berman, P.W., Phonrat, B., Suntharasamai, P., Raktam, S., Srisuwanvilai, L.O., et al., 2004. Phase I/II study of a candidate vaccine designed against B and E subtypes of HIV-1. *J. Acquir. Immune Defic. Syndr.* 37, 1160–1165.
- Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., et al., 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. *J. Infect. Dis.* 194, 1661–1671.
- Pitisuttithum, P., Nitayaphan, S., Chariyalertsak, S., Karasavvas, N., Kaewkungwal, J., Ngauy, V., et al., 2014. RV306, an evaluation of a 48 Week ALVAC-HIV AIDSvax B/E vaccination regimen in Thailand: Participation rates for optional specimen collections. *AIDS Res. Hum. Retrovir.* 30, A264.
- Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., et al., 2009. Vaccination with ALVAC and AIDSvax to prevent HIV-1 infection in Thailand. *N. Engl. J. Med.* 361, 2209–2220.
- Ruberti, F., Cattaneo, A., Bradbury, A., 1994. The use of the RACE method to clone hybridoma cDNA when V region primers fail. *J. Immunol. Methods* 173, 33–39.
- Schwartz, D.H., Gorse, G., Clements, M.L., Belshe, R., Izu, A., Duliege, A.M., et al., 1993. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIB rgp120 subunit vaccine. *Lancet* 342, 69–73.
- Smith, D.H., Winters-Digiaccinto, P., Mitiku, M., O'Rourke, S., Sinangil, F., Wrin, T., et al., 2010. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. *PLoS One* 5, e12076.
- Steger, K., Brady, J., Wang, W., Duskin, M., Donato, K., Peshwa, M., 2015. CHO-S antibody titers > 1 gram/liter using flow electroporation-mediated transient gene expression followed by rapid migration to high-yield stable cell lines. *J. Biomol. Screen.* 20, 545–551.

- Svasti, J., Milstein, C., 1972. The complete amino acid sequence of a mouse kappa light chain. *Biochem. J.* 128, 427–444.
- Tjio, J.H., Puck, T.T., 1958. Genetics of somatic mammalian cells: II Chromosomal constitution of cells in tissue culture. *J. Exp. Med.* 108, 259–268.
- Tomaras, G.D., Ferrari, G., Shen, X., Alam, S.M., Liao, H.X., Pollara, J., et al., 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. *Proc. Natl. Acad. Sci. U. S. A.* 110, 9019–9024.
- Wang, K., Tomaras, G.D., Jegaskanda, S., Moody, M.A., Liao, H.X., Goodman, K.N., et al., 2017. Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1. *J. Virol.* 91.
- Ye, J., Ma, N., Madden, T.L., Ostell, J.M., 2013. IgBLAST: an immunoglobulin variable domain sequence analysis tool. *Nucleic Acids Res.* 41, W34–W40.
- Yu, B., Morales, J.F., O'Rourke, S.M., Tatsuno, G.P., Berman, P.W., 2012. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. *PLoS One* 7, e43903.